Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

This double-blinded, placebo-control trial clinical trial aims to investigate the effect of IV oxytocin infusion on peri-operative opioid consumption following a minimally invasive hysterectomy under general anesthesia.patients population will be women who have been scheduled for an elective, minimally invasive hysterectomy at Beth Israel Deaconness Medical Center.We hypothesize that, compared to a placebo, exposure to intravenous (IV) oxytocin will reduce the amount of opioid consumption for women after a minimally invasive hysterectomy procedure.

Inclusion Criteria:women the age of 18-65 years old undergoing elective, minimally invasive hysterectomy under general anesthesiaExclusion Criteria:ASA 4 or greaterAdditional surgical components including but not limited to: minor laparotomy, omentectomy, cystectomy, and lymph node dissection.Allergies to any study medication: acetaminophen, ketorolac, hydromorphone, oxycodone, fentanyl, gabapentin, pregabalin.Epidural/Regional anesthesia use for intra-operative or post-operative pain.